RenovoRx, Inc. (NASDAQ:RNXT – Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 62,700 shares, a growth of 85.0% from the March 15th total of 33,900 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily volume of 72,400 shares, the short-interest ratio is presently 0.9 days.
Separately, Zacks Investment Research raised shares of RenovoRx from a “sell” rating to a “hold” rating in a report on Friday.
Several large investors have recently bought and sold shares of RNXT. Virtu Financial LLC bought a new position in shares of RenovoRx during the 4th quarter valued at about $64,000. Citadel Advisors LLC bought a new position in shares of RenovoRx during the 3rd quarter valued at about $73,000. Two Sigma Securities LLC bought a new position in shares of RenovoRx during the 3rd quarter valued at about $108,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of RenovoRx in the third quarter worth about $125,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in shares of RenovoRx in the third quarter worth about $247,000. Institutional investors own 1.60% of the company’s stock.
RenovoRx (NASDAQ:RNXT – Get Rating) last released its earnings results on Wednesday, March 30th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.04. Research analysts expect that RenovoRx will post -1 earnings per share for the current fiscal year.
About RenovoRx (Get Rating)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.